Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeBIOTECHNOLOGYCreatv Microtech Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell...

Creatv Microtech Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test

Data Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Virtual Meeting

June 12, 2020

Creatv Microtech, is a privately-held biotechnology company has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy (CRT) and consolidated immunotherapy.

Clinical data presented at the ASCO 2020 virtual annual meeting shows the ability to predict which NSCLC patients will benefit from anti-PD-L1/PD-1 immunotherapies. “We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT,” said Dr. Cha-Mei Tang, CEO of Creatv Microtech. “Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies.” Currently, no other blood test can predict immunotherapy treatment response for lung cancer.

Creatv’s poster, Sequential Monitoring of Circulating Stromal Cells from Blood is Predictive of Progression in NSCLC patients undergoing anti-PD-L1 Therapy after Definitive Chemoradiation Therapy, Abstract ID: 3051, highlights the performance of the LifeTracDxTM test. In a completely novel concept, the test analyzes patients’ immune response to the presence of cancer, isolating stromal cells from cancer sites that have migrated into the bloodstream. Creatv demonstrated that a particular subtype of circulating stromal cell, named Cancer-Associated Macrophage-Like cells (CAMLs), can be used in patients with cancer to rapidly track response to new therapies. CAMLs are phagocytic myeloid cells derived from the patient’s immunological response to inflammation caused by active malignancy.

We have previously shown that in solid tumors, patients with CAMLs larger than 50µm in size have poorer prognosis, with shorter progression-free survival (PFS) and overall survival (OS). In this poster, Creatv Microtech presents the findings from a two-year single blind prospective study of 104 NSCLC patients with Stage II-III or with locally recurrent disease treated with standard CRT, followed by anti-PD-L1 or PD-1 therapies (i.e. durvalumab, pembrolizumab, etc.). Blood draws were taken at baseline, directly after CRT completion and after approximately 2.5 months of anti-PD-L1/PD-1 therapy. The LifeTracDxTM tests at both time points were able to predict good PFS and OS by identifying patients responding well to the immunotherapy based on CAML size.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy